ND: |
ME12405690 |
PMID: |
12405690 |
LR: |
20061115 |
CED: |
20021030 |
DCO: |
20030226 |
Autoren: |
Fenton JI; Chlebek-Brown KA; Caron JP; Orth MW |
Titel: |
Effect of glucosamine on interleukin-1-conditioned articular cartilage. |
Quelle: |
Equine veterinary journal. Supplement (34); p. 219-23 /200209/ |
PM: |
Print |
SU: |
IM |
Sprache: |
English |
CY: |
England |
JID: |
9614088 |
Institution: |
Department of Animal Science, Michigan State University, East Lansing 48824, USA. |
DT: |
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. |
Schlagwörter |
CT: |
ANIMALS; CARTILAGE, ARTICULAR/*drug effects; CARTILAGE, ARTICULAR/metabolism; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSAMINE/*pharmacology; GLUCOSAMINE/therapeutic use; HORSE DISEASES/*drug therapy; HORSE DISEASES/metabolism; HORSES; INTERLEUKIN-1/pharmacology; MATRIX METALLOPROTEINASE 3/antagonists & inhibitors; MATRIX METALLOPROTEINASE 3/drug effects; MATRIX METALLOPROTEINASE 3/metabolism; MATRIX METALLOPROTEINASES/drug effects; MATRIX METALLOPROTEINASES/metabolism; NITRIC OXIDE/biosynthesis; OSTEOARTHRITIS/drug therapy; OSTEOARTHRITIS/metabolism; OSTEOARTHRITIS/*veterinary |
CTG: |
TIER; KNORPEL, GELENK-/*Arzneimittelwirkungen; KNORPEL, GELENK-/Stoffwechsel; ZELLEN, KULTIVIERTE; DOSIS-WIRKUNGSBEZIEHUNG, ARZNEIMITTEL-; GLUCOSAMIN/*Pharmakologie; GLUCOSAMIN/therapeutische Anwendung; PFERDEKRANKHEITEN/*Arzneimitteltherapie; PFERDEKRANKHEITEN/Stoffwechsel; PFERDE; INTERLEUKIN-1/Pharmakologie; STROMELYSIN 1/Antagonisten & Inhibitoren; STROMELYSIN 1/Arzneimittelwirkungen; STROMELYSIN 1/Stoffwechsel; MATRIX-METALLOPROTEINASEN/Arzneimittelwirkungen; MATRIX-METALLOPROTEINASEN/Stoffwechsel; STICKSTOFFMONOXID/Biosynthese; OSTEOARTHROSE/Arzneimitteltherapie; OSTEOARTHROSE/Stoffwechsel; OSTEOARTHROSE/*Veterinärmedizin |
TE: |
Interleukin-1; Nitric Oxide/10102-43-9; Glucosamine/3416-24-8; Matrix Metalloproteinases/E.C. 3.4.24.-; Matrix Metalloproteinase 3/E.C. 3.4.24.17 |
CR: |
10102-43-9; 3416-24-8; E.C. 3.4.24.-; E.C. 3.4.24.17 |
AB: |
Glucosamine inhibits recombinant human interleukin-1 stimulated cartilage degradation in equine cartilage explants. Recently, recombinant equine interleukin-1 has been cloned and purified. Therefore, the objective of this study was to characterise the effects of glucosamine on indices of cartilage degradation in recombinant equine IL-1beta-stimulated equine articular cartilage explants. Cartilage discs were harvested from the weight-bearing region of the articular surface of the antebrachiocarpal and middle carpal joints of horses (age 2-8 years) and cultured under standard conditions. Explants were exposed to recombinant equine interleukin-1beta (reIL-1beta) on Days 1-4 in the presence or absence of glucosamine (0.25, 2.5 or 25 mg/ml), with appropriate controls. Nitric oxide, prostaglandin E2, sulphated proteoglycan, stromelysin and gelatinase/collagenase activity released into conditioned media and total tissue proteoglycan content were measured as indicators of cartilage catabolism. Glucosamine inhibited cartilage catabolic responses in a dose dependent manner that was statistically significant at a dose of 0.25 mg/ml for stromelysin activity and 2.5 mg/ml for collagenase/gelatinase activity. At 25 mg/ml glucosamine also prevented IL-1beta-induced increases in nitric oxide production, prostaglandin E2 and proteoglycan release to media. Glucosamine prevents equine articular cartilage degradation experimentally induced by reIL-1beta in vitro. These data provide further support for the use of glucosamine in treatment or prevention of cartilage loss in athletic horses. |